Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

被引：0

作者：

Voorhees, Peter M. ^{[1
]}

Kaufman, Jonathan L. ^{[2
]}

Laubach, Jacob P. ^{[3
]}

Sborov, Douglas W. ^{[4
]}

Reeves, Brandi ^{[5
]}

Rodriguez, Cesar ^{[6
]}

Chari, Ajai ^{[7
]}

Silbermann, Rebecca W. ^{[8
]}

Costa, Luciano J. ^{[9
]}

Anderson, Larry D. ^{[10
]}

Nathwani, Nitya ^{[11
]}

Shah, Nina D. ^{[12
]}

Efebera, Yvonne A. ^{[13
]}

Costello, Caitlin L. ^{[14
]}

Jakubowiak, Andrzej ^{[15
]}

Wildes, Tanya M. ^{[16
]}

Orlowski, Robert Z. ^{[17
]}

Shain, Kenneth H. ^{[18
]}

Cowan, Andrew J. ^{[19
]}

Murphy, Sean ^{[20
]}

Lutska, Yana ^{[20
]}

Pei, Huiling ^{[21
]}

Ukropec, Jon ^{[22
]}

Vermeulen, Jessica ^{[23
]}

de Boer, Carla ^{[23
]}

Hoehn, Daniela ^{[20
]}

Lin, Thomas S. ^{[20
]}

Richardson, Paul G. ^{[3
]}

机构：

[1] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[3] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Univ Utah, Sch Med, Huntsman Canc Inst, Salt Lake City, UT USA

[5] Univ N Carolina, Chapel Hill, NC 27515 USA

[6] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA

[7] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA

[8] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[9] Univ Alabama Birmingham, Birmingham, AL USA

[10] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Hematol Oncol, Dallas, TX USA

[11] City Hope Comprehens Canc Ctr, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Duarte, CA USA

[12] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[13] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[14] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[15] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[16] Washington Univ, Div Oncol, Sect Med Oncol, St Louis, MO USA

[17] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[18] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, St Petersburg, FL USA

[19] Univ Washington, Div Med Oncol, Seattle, WA USA

[20] Janssen Sci Affairs LLC, Horsham, PA USA

[21] Janssen Res & Dev LLC, Titusville, NJ USA

[22] Janssen Global Med Affairs, Horsham, PA USA

[23] Janssen Res & Dev LLC, Leiden, Netherlands

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

691

引用

页数：7

共 50 条

[31] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
Suzuki, Kazuhito
Tsukada, Nobuhiro
Nishimura, Noriko
Nagata, Yasuyuki
Okazuka, Kiyoshi
Mishima, Yuko
Yokoyama, Masahiro
Nishiwaki, Kaichi
Ishida, Tadao
Yano, Shingo
Terui, Yasuhito
Suzuki, Kenshi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (01) : 103 - 111
[32] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase Ill study (CEPHEUS)
Zweegman, Sonja
Usmani, Saad Zafar
Chastain, Katherine
Carey, Jodi
Ren, Karen
Smith, Elena
Krevvata, Maria
Wang, Jianping
Vermeulen, Jessica
Facon, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[33] Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
Bhutani, Manisha
Robinson, Myra
Atrash, Shebli
Watts, Nicole
Paul, Barry
Chhabra, Saurabh
Korde, Neha
Begic, Xhevahire
Foureau, David M.
Chung, David J.
Pineda-Roman, Mauricio
Koya, Brinda
Varga, Cindy
Ai, Jing
Daniels, Natonya
Norek, Sarah
Sutton, Sara A.
Anderson, Michelle B.
Jewell, Ashley N.
Eldridge, Paul W.
Acampora, Donna
Symanowski, James T.
Costa, Luciano J.
Usmani, Saad
Voorhees, Peter M.
BLOOD, 2022, 140 : 4393 - 4395
[34] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: A multicenter retrospective comparative analysis
Nishimura, Noriko
Suzuki, Kazuhito
Tsukada, Nobuhiro
Nagata, Yasuyuki
Okaduka, Kiyoshi
Mishima, Yuko
Yokoyama, Masahiro
Nishiwaki, Kaichi
Ishida, Tadao
Yano, Shingo
Terui, Yasuhito
Suzuki, Kenshi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E214 - E215
[35] Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN
Silbermann, Rebecca
Laubach, Jacob
Kaufman, Jonathan L.
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Costa, Luciano J.
Anderson, Larry D.
Nathwani, Nitya
Shah, Nina
Bumma, Naresh
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Gries, Katharine S.
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Richardson, Paul G.
Usmani, Saad
Voorhees, Peter M.
BLOOD, 2022, 140 : 1146 - 1149
[36] Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis
Dimopoulos, Meletios
Sonneveld, Pieter
Rodriguez-Otero, Paula
Hang Quach
Ho, P. Joy
Beksac, Meral
Hulin, Cyrille
Antonioli, Elisabetta
Leleu, Xavier
Mangiacavalli, Silvia
Perrot, Aurore
Cavo, Michele
Belotti, Angelo
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
Nijhof, Inger S.
van de Donk, Niels
Katodritou, Eirini
Sitthi-Amorn, Anna
de Boer, Carla J.
Carson, Robin
Blade, Joan
Moreau, Philippe
Boccadoro, Mario
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S30 - S31
[37] Daratumumab (DARA) plus Bortezomib/ Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study
Moreau, Philippe
Hulin, Cyrille
Perrot, Aurore
Arnulf, Bertrand
Belhadj, Karim
Benboubker, Lotfi
Zweegman, Sonja
Caillon, Helene
Caillot, Denis
Avet-Loiseau, Herve
Delforge, Michel
Dejoie, Thomas
Facon, Thierry
Sonntag, Cecile
Fontan, Jean
Mohty, Mohamad
Jie, Kon-Siong
Karlin, Lionel
Kuhnowski, Frederique
Lambert, Jerome
Leleu, Xavier
Macro, Margaret
Orsini-Piocelle, Frederique
Roussel, Murielle
de Colella, Jean Marc Schiano
van de Donk, Niels W. C. J.
Wuilleme, Soraya
Broijl, Annemiek
Touzeau, Cyrille
Tiab, Mourad
Marolleau, Jean-Pierre
Meuleman, Nathalie
Vekemans, Marie-Christiane
Westerman, Matthijs
Klein, Saskia K.
Levin, Mark-David
Offner, Fritz
Escoffre-Barbe, Martine
Eveillard, Jean-Richard
Garidi, Reda
Hua, Winnie
Wang, Jianping
Tuozzo, Alba
de Boer, Carla J.
Rowe, Melissa
Vanquickelberghe, Veronique
Carson, Robin
Vermeulen, Jessica
Corre, Jill
Sonneveld, Pieter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S560 - S561
[38] Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA
Sonneveld, Pieter
Attal, Michel
Perrot, Aurore
Hulin, Cyrille
Caillot, Denis
Facon, Thierry
Leleu, Xavier
Belhadj-Merzoug, Karim
Karlin, Lionel
Benboubker, Lofti
Levin, Mark-David
Minnema, Monique
Westerman, Matthijs
Delforge, Michel
Zweegman, Sonja
Pei, Lixia
de Boer, Carla
Vanquickelberghe, Veronique
Kampfenkel, Tobias
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E2 - E3
[39] Real-World Data on the Daratumumab Plus Bortezomib, Thalidomide and Dexamethasone Followed by Lenalidomide Maintenance for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
Crusoe, Edvan de Queiroz
Ribeiro, Glaciano
Moura, Fernanda
Costa, Abel
Aranha, Milton
Bittencourt, Rosane
Ribeiro, Eduardo
Neto, Jorge
Cunha, Rafael
Mattos, Ederson
Braga, Walter
Lima, Juliana Souza
Gusmao, Breno
Lopes, Danielle Ovigli
Berg, Luiza
Souto, Joao
Maiolino, Angelo
Hungria, Vania T. M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S223 - S223
[40] Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN
Silbermann, Rebecca
Laubach, Jacob
Kaufman, Jonathan L.
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Costa, Luciano J.
Anderson, Larry D.
Nathwani, Nitya
Shah, Nina
Bumma, Naresh
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Gries, Katharine S.
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Voorhees, Peter M.
Usmani, Saad Z.
Richardson, Paul G.
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1257 - 1268

← 1 2 3 4 5 →